{"disease":{"id":"oligodendroglioma-oligoastrocytoma","name":"oligodendroglioma oligoastrocytoma"},"drugs":{"marketed":[],"pipeline":[],"offLabel":[],"totalMarketed":0,"totalPipeline":0},"trials":{"data":[{"nct_id":"NCT00035373","title":"Eligibility Screening of Patients With Central Nervous System Tumors for the National Cancer Institute s (NCI) Clinical Research Protocols","phase":"","overall_status":"TERMINATED","enrollment_count":767,"lead_sponsor_name":"National Cancer Institute (NCI)","has_results":false},{"nct_id":"NCT03180502","title":"Proton Beam or Intensity-Modulated Radiation Therapy in Preserving Brain Function in Patients With IDH Mutant Grade II or III Glioma","phase":"PHASE2","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":120,"lead_sponsor_name":"NRG Oncology","has_results":false},{"nct_id":"NCT01849952","title":"Evaluating the Expression Levels of MicroRNA-10b in Patients With Gliomas","phase":"","overall_status":"TERMINATED","enrollment_count":94,"lead_sponsor_name":"Dartmouth-Hitchcock Medical Center","has_results":false},{"nct_id":"NCT04755023","title":"Primary Chemotherapy by BCNU-TMZ Combination in Newly Diagnosed Anaplastic Oligodendrocytic Tumors: Phase II Trial With Translational Molecular Analysis","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":53,"lead_sponsor_name":"Assistance Publique Hopitaux De Marseille","has_results":false},{"nct_id":"NCT04623931","title":"Chemotherapy and Radiation Therapy for the Treatment of IDH Wildtype Gliomas or Non-histological (Molecular) Glioblastomas","phase":"PHASE2","overall_status":"RECRUITING","enrollment_count":40,"lead_sponsor_name":"M.D. Anderson Cancer Center","has_results":false},{"nct_id":"NCT00303849","title":"Carboplatin, Melphalan, Etoposide Phosphate, Mannitol, and Sodium Thiosulfate in Treating Patients With Previously Treated Brain Tumors","phase":"PHASE1, PHASE2","overall_status":"COMPLETED","enrollment_count":33,"lead_sponsor_name":"OHSU Knight Cancer Institute","has_results":false},{"nct_id":"NCT02549833","title":"Neo-adjuvant Evaluation of Glioma Lysate Vaccines in WHO Grade II Glioma","phase":"PHASE1","overall_status":"COMPLETED","enrollment_count":28,"lead_sponsor_name":"Jennie Taylor","has_results":false},{"nct_id":"NCT02023905","title":"Everolimus With and Without Temozolomide in Adult Low Grade Glioma","phase":"PHASE2","overall_status":"TERMINATED","enrollment_count":27,"lead_sponsor_name":"University of California, San Francisco","has_results":true},{"nct_id":"NCT02015819","title":"Genetically Modified Neural Stem Cells, Flucytosine, and Leucovorin for Treating Patients With Recurrent High-Grade Gliomas","phase":"PHASE1","overall_status":"COMPLETED","enrollment_count":16,"lead_sponsor_name":"City of Hope Medical Center","has_results":true},{"nct_id":"NCT02924038","title":"A Study of Varlilumab and IMA950 Vaccine Plus Poly-ICLC in Patients With WHO Grade II Low-Grade Glioma (LGG)","phase":"PHASE1","overall_status":"TERMINATED","enrollment_count":14,"lead_sponsor_name":"Nicholas Butowski","has_results":true},{"nct_id":"NCT03072134","title":"Neural Stem Cell Based Virotherapy of Newly Diagnosed Malignant Glioma","phase":"PHASE1","overall_status":"COMPLETED","enrollment_count":12,"lead_sponsor_name":"Northwestern University","has_results":true},{"nct_id":"NCT01635283","title":"Vaccine for Patients With Newly Diagnosed or Recurrent Low-Grade Glioma","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":5,"lead_sponsor_name":"Jonsson Comprehensive Cancer Center","has_results":true},{"nct_id":"NCT02168270","title":"Temozolomide and Ascorbic Acid in Treating Patients With Recurrent High-Grade Glioma","phase":"PHASE1","overall_status":"TERMINATED","enrollment_count":4,"lead_sponsor_name":"University of Nebraska","has_results":true},{"nct_id":"NCT01281982","title":"(11C)dLop as a Marker of P-Glycoprotein Function in Patients With Gliomas","phase":"","overall_status":"TERMINATED","enrollment_count":2,"lead_sponsor_name":"National Cancer Institute (NCI)","has_results":false},{"nct_id":"NCT03353896","title":"NovoTTF-200A Device in Treating Patients With Newly Diagnosed High Risk Oligodendroglioma","phase":"NA","overall_status":"WITHDRAWN","enrollment_count":0,"lead_sponsor_name":"University of Southern California","has_results":false}],"total":15},"guidelines":[],"source":"Drug Landscape verified database"}